Edition:
United Kingdom

BeyondSpring announces first patient enrolled in China


Thursday, 26 Oct 2017 

Oct 26 (Reuters) - BeyondSpring Inc ::BeyondSpring announces the first patient enrolled in China in its global phase 2/3 trial with plinabulin for the prevention of chemotherapy-induced neutropenia.BeyondSpring-‍look forward to top line results, later in 2017, comparing plinabulin with pegfilgrastim from phase 2 portion of the phase 2/3 trial. 

Company Quote

19.35
 --
15 Jul 2019